Galapagos NV
A biotechnology company focused on a rapid, decentralized cell therapy platform.
GLPG | BR
Overview
Corporate Details
- ISIN(s):
- BE0003818359
- LEI:
- 549300QKJ78IY0IOV655
- Country:
- Belgium
- Address:
- Industriepark Mechelen Noord, Generaal De Wittelaan L11 A3, 2800 Mechelen
- Website:
- https://www.glpg.com/
- Sector:
- Manufacturing
Description
Galapagos NV is a biotechnology company focused on transforming patient outcomes through scientific innovation. The company is strategically concentrating its efforts on its cell therapy platform, which is engineered for the scalable, decentralized, and rapid production of next-generation treatments. A key feature of this platform is a median 7-day vein-to-vein delivery time. In parallel with this focus, Galapagos is actively seeking partners to take over its portfolio of small molecule assets, including its TYK2 inhibitor program for autoimmune indications. This strategic shift allows the company to prioritize the growth and development of its cell therapy pipeline through internal discovery, partnerships, and acquisitions.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Type / Size | Actions | |
|---|---|---|---|---|---|
| 2024-09-30 22:01 |
Galapagos receives transparency notification from EcoR1 Capital.pdf
|
English | PDF • 186.4 KB | ||
| 2024-09-30 22:01 |
Galapagos ontvangt transparantieverklaring van EcoR1 Capital.pdf
|
Dutch | PDF • 186.6 KB | ||
| 2024-09-17 08:17 |
Galapagos receives transparency notification from EcoR1 Capital
|
English | PDF • 171.8 KB | ||
| 2024-09-17 08:17 |
Galapagos receives transparency notification from EcoR1 Capital
|
Dutch | PDF • 183.0 KB | ||
| 2024-09-16 22:01 |
Galapagos receives transparency notification from EcoR1 Capital.pdf
|
English | PDF • 171.8 KB | ||
| 2024-09-16 22:01 |
Galapagos ontvangt transparantieverklaring van EcoR1 Capital.pdf
|
Dutch | PDF • 183.0 KB | ||
| 2024-09-04 07:45 |
Galapagos receives transparency notification from FMR LLC
|
Dutch | PDF • 174.5 KB | ||
| 2024-09-04 07:45 |
Galapagos receives transparency notification from FMR LLC
|
English | PDF • 151.1 KB | ||
| 2024-09-03 22:01 |
GLPG EN PR_FMR LLC 30 August 2024_ENG.pdf
|
English | PDF • 151.1 KB | ||
| 2024-09-03 22:01 |
GLPG EN PR_FMR LLC 30 August 2024_NL.pdf
|
Dutch | PDF • 174.5 KB | ||
| 2024-08-23 07:40 |
Galapagos announces FDA clearance of IND application for Phase 1/2 ATALANTA-1 s…
|
Dutch | PDF • 206.9 KB | ||
| 2024-08-23 07:40 |
Galapagos announces FDA clearance of IND application for Phase 1/2 ATALANTA-1 s…
|
English | PDF • 179.5 KB | ||
| 2024-08-23 07:00 |
GLPG Press Release IND Clearance_ENG_FINAL.pdf
|
English | PDF • 179.5 KB | ||
| 2024-08-23 07:00 |
GLPG Press Release IND Clearance_NL_FINAL.pdf
|
Dutch | PDF • 206.9 KB | ||
| 2024-08-21 08:18 |
Galapagos ontvangt transparantieverklaring van FMR LLC
|
Dutch | PDF • 189.4 KB |
Automate Your Workflow. Get a real-time feed of all Galapagos NV filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Galapagos NV
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Galapagos NV via our API.
Peer Companies
